All News

antisynthetase,myositis,nail,erythema

Clinical Associations with Myositis Antibodies

Jack Cush, MD

While myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) may have prognostic value through their clinical associations, many patients will not have them and overall, they are poorly predictive of a malignancy risk. 

Read Article
RheumNow Podcast square

RheumNow Podcast – Jack of All Subspecialties (10.1.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article
RheumNow Podcast square

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Jack Cush, MD

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID breakthrough infections, and statin use and the risk of RA, as I review the news and journal articles from the past week on RheumNow.

Read Article
arm,muscle,weak

High Comorbidity Rates with Inclusion Body Myositis

Jack Cush, MD

Inclusion body myositis (IBM) patients tend to be older than those with idiopathic inflammatory myositis (IIM), but the scope of disease beyond their myositis is not appreciated.

Read Article
Dr. Fiorentino on cancer risk stratification and screening in myositis. Come chat at noon in the Myositis Community Hub to learn more! #ACR21 #ACRAmbassador https://t.co/I0iQuPAuOl
Veena Katikineni VeenaRheumMD ( View Tweet)
Thanks Dr David Fiorentino for his talk on CA and myositis! ⬆️risk: - DM - >45-50yo - males - TIF1-gamma Ab (4.7RR of CA) - NXP2 - low CK - dysphagia ⬇️ risk: - synthetase Ab - raynaud - ILD - inflamm arth 🚨TIF1-gamma🚨 - ovarian CA (older, IgG2) #ACR21 #ACRAmbassador

Vaneet K Sandhu, MD (she/her/hers) vksandhumd ( View Tweet)

I remember, not that long ago, inclusion body myositis evoked resignation, for pts & clinicians. A bizarre condition where standard of care was counselling/mitigation Now there hope might be on the horizon Exciting to see the science & a feasible target #ACR21 ABSTL07 @RheumNow https://t.co/CYiAXIEA0Q
David Liew drdavidliew ( View Tweet)
Dr Preger report 9 novel aminoacyl tRNA synthetases in IIM patients. May these allow us to spare more patients biopsy? Abstr#0001 #ACR21 @RheumNow https://t.co/ikNXCEOeuj
Richard Conway RichardPAConway ( View Tweet)
Knowledge Bowl at #ACR21 ⭐️Approximately half of patients with IIM who develop pneumomediastinum have this subtype of dermatomyositis. ➡️Amyopathic (MDA5) dermatomyositis @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Dr Bass on the ICI M triad: Myositis, Myocarditis, Myasthenia--> Strongly a/w morbidity & mortality ~0.4% frequency, mortality 22% when myositis alone ~Overlap (+ myasthenia or myocarditis) more common w/ combination ICI, mortality 42% #ACR21 #ACRAmbassador https://t.co/g50tzAYhlS
Veena Katikineni VeenaRheumMD ( View Tweet)
If obvious dermatomyositis, you don’t need EMG for dx but may use for severity of involvement or if failing Rx or r/o steroid myopathy. For ?polymyositis ALWAYS do bx and often do EMG as broad differential #ACR21 @RheumNow https://t.co/L1xu3OuRYJ

Links:

Janet Pope Janetbirdope ( View Tweet)

@KatGilekMD @RichardPAConway @RheumNow @drhectorchinoy EMG/NCS can help uncover various neurological disorders including muscle dystrophies. Obviously it depends on center and expertise. Both MRI and EMG are useful and have different complementary utilities in Myositis. Many centers are not able to perform or interpret MRI reliably.

Rohit Aggarwal docrota ( View Tweet)

@NU_Rheum_MSK_US @RichardPAConway @drhectorchinoy @RheumNow Muscle ultrasound can be very useful but it is not ready for prime time currently to be used to do muscle biopsies. Perhaps in few years once we know how to target the muscle for biopsy.

Rohit Aggarwal docrota ( View Tweet)

Clinical (Peds Rheum) Pearl at #ACR21 by Dr. John Stone: ⭐️Dilated capillaries at the eyelid margin is the last cutaneous sign to resolve in inflammatory myositis! ⭐️Do not stop treatment until this sign is gone! #ACRBest @RheumNow https://t.co/5H3Q9mTN9x
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR21 #Abstr0690 Great work by @didemsayginmd et al. 2016 ACR-EULAR Myositis Response Criteria concurred with patient-reported outcomes (muscle disease activity, strength, pain, fatigue, physical function, quality of life and physical activity) @RheumNow https://t.co/IV3mAXKhbt https://t.co/GWC6IDcJSm

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Retrospective study of FAERS database: 186 irAE w/rheum manifestation 👉4.7% of all AEs 👉Arthritis, myositis, Sjogren, sarcoidosis were frequent 👉myositis assc w/ durvalumab, avelumab, atezolimumab and cemiplimab #ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/t8UQWQicFc https://t.co/FGo6WCDQTp

Links:

TheDaoIndex KDAO2011 ( View Tweet)
KL-6, Anti-Ku, anti-CENPB were assoc'd w/ #myositis &/or ILD in #lupus patients accdg to this study by Dr. T Cotton et al. This may help identify patients at risk for developing such. @RheumNow #ACR21 abs0330 https://t.co/p0uxBOTLZm
sheila RHEUMarampa ( View Tweet)
In case you missed it…a popular read. Clinical Associations with Myositis Antibodies Read the full article on #RheumNow https://t.co/tzPU1scc8x https://t.co/pmmtmIuz31

Links:

Dr. John Cush RheumNow ( View Tweet)
Clinical Associations with Myositis Antibodies Read the full post on #RheumNow https://t.co/tzPU1scc8x https://t.co/F537tPAQTU

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: JAK inhibitors as potential treatment for Juvenile Dermatomyositis: nice review of the biology of JAKi effects and the reports of JAKi success in adults and kids with IIM https://t.co/k3qunsCdBN https://t.co/nyqMo6vh88

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×